Abstract:BACKGROUND: Activated epidermal growth factor receptor (EGFR) mutation is the main pathogenic cause of non-small cell lung cancer (NSCLC) in Asia. However, the impact of plasma EGFR mutation abundance, especially of the ultra-low abundance of EGFR mutation detected by highly sensitive techniques on clinical outcomes of first-line EGFR tyrosine kinase inhibitors (TKIs) for advanced NSCLC patients remains unclear.METHODS: We qualitatively detected baseline EGFR status of NSCLC tissues using amplification-refractory mutation system and quantified the plasma abundance of EGFR mutations through next-generation sequencing (NGS). Every 8-12 weeks, we performed dynamic detection of plasma mutation abundance and imaging evaluation. We analyzed the association between plasma abundance of EGFR sensitizing mutations, tumor size, tumor shrinkage percentage, concomitant TP53 mutations, and clinical response to TKIs.RESULTS: This prospective study enrolled 135 patients with advanced NSCLC. The objective response rate (ORR) and disease control rate (DCR) for EGFR mutation-positive patients were 50.0% and 87.0%, respectively. When the cutoff value of plasma EGFR mutation abundance was 0.1%, the ORRs of TKI-treated patients were significantly different (60.0% for the >0.1% group vs. 21.4% for the ≤0.1% group, P=0.028). Median progression-free survival (PFS) was significantly longer for participants with a mutation abundance above 0.1% compared to those with a 0.01-0.1% abundance (log rank, P=0.0115). There was no significant association between plasma abundance of EGFR sensitizing mutations and tumor size, tumor shrinkage percentage, or concomitant TP53 mutations. Cox multivariate analysis demonstrated that plasma mutation abundance was an independent predictive factor for PFS [hazard ratio (HR) 2.41, 95% confidence interval (CI): 1.12-5.20; P=0.025]. We identified 11 participants with the acquired T790M resistance mutation according to serial dynamic plasma samples.CONCLUSIONS: Liquid biopsy screening based on highly sensitive NGS is reliable for detecting drug resistance and actionable somatic mutations. The plasma abundance of the EGFR driver mutation affected clinical response to EGFR-TKIs in advanced NSCLC patients; prolongation of PFS was also observed in patients with an ultra-low abundance of EGFR sensitizing mutations.

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Effect Of Egfr Mutations On Gefitinib In Advanced Previous Treated Non-Small-Cell Lung Cancer

Mutation Abundance Affects the Efficacy of Egfr Tyrosine Kinase Inhibitor Readministration in Non-Small-Cell Lung Cancer with Acquired Resistance

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Detection and Dynamic Changes of Egfr Mutations from Circulating Tumor Dna As A Predictor of Survival Outcomes in Nsclc Patients Treated with First-Line Intercalated Erlotinib and Chemotherapy

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Comparison of clinical outcome and efficacy of patients with advanced non-small cell lung cancer Harbouring different epidermal growth factor receptor mutations

Relative Abundance of EGFR Mutations Predicts Benefit from Gefitinib Treatment for Advanced Non-Small-cell Lung Cancer.

Non-invasive and Quantitative Analysis for EGFR T790M Mutation in the Patients with Advanced Non-Small Cell Lung Cancer Received EGFR-TKI Therapy.

Egfr Mutation Status In Plasma And Tumor Tissues In Non-Small Cell Lung Cancer Serves As A Predictor Of Response To Egfr-Tki Treatment

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer

A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

Impact of Plasma EGFR Mutation Fractions on Response to First Generation Tyrosine-Kinase Inhibitor in Treatment of Naïve Non-Small Cell Lung Cancer Patients

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients

Intratumoral Heterogeneity of EGFR Mutation and Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer.

Longitudinal Evaluation of Egfr Mutation in Plasma for Non-Small Cell Lung Cancer Patients with Front-Line Chemotherapy

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer